The second half of 2026 is shaping up to be an important period for regulatory activity, with the U.S. Food and Drug Administration expected to review therapies across oncology, neurology, nephrology, infectious diseases, hematology, and rare disorders. The FDA approvals H2 2026 pipeline highlights the industry's growing emphasis on precision medicine, advanced biologics, targeted treatments,...